Stockreport

Sunovion Announces Acceptance by the U.S. FDA of the New Drug Application for Dasotraline for the Treatment of Adults with Moderate-to-Severe Binge Eating Disorder

SUMITOMO CHEM UNSP/ADR  (SOMMY) 
NASDAQ:AMEX Investor Relations: sumitomo-chem.co.jp/english/ir
PDF -Binge eating disorder (BED) is estimated to affect 4.1 million Americans and may occur at a rate that is three times higher than anorexia and bulimia combined1- MARL [Read more]